Medicine and Dentistry
Venous Thromboembolism
100%
Cohort Analysis
78%
Malignant Neoplasm
56%
Pulmonary Embolism
50%
Anticoagulation
23%
Psychoactive Drug
20%
Lung Cancer
20%
Atrial Fibrillation
19%
Antithrombotic
19%
Antithrombotic Therapy
19%
Adolescent
17%
Diseases
17%
Anticoagulant Therapy
16%
Psychological Well-Being
16%
Bleeding
16%
Patient-Reported Outcome
16%
Non Small Cell Lung Cancer
15%
Health Outcomes
12%
Vitamin K Antagonist
12%
Rehabilitation Engineering
11%
Attributable Risk
11%
Cardiovascular System
10%
Phlebothrombosis
9%
Abdominal Aortic Aneurysm
9%
Multiple Chronic Conditions
9%
Outcome Assessment
9%
Aortic Aneurysm
9%
Oncologist
9%
Diabetes Mellitus
9%
Drug Use
9%
Systematic Review
9%
Physical Capacity
9%
Personal Experience
9%
Cost-Effectiveness Analysis
9%
Mental Health
8%
Quality of Life
7%
Insulin Dependent Diabetes Mellitus
6%
Cancer Therapy
6%
Apoplexy
5%
Thromboembolism
5%
Cancer Staging
5%
Secondary Prevention
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
87%
Venous Thromboembolism
70%
Malignant Neoplasm
46%
Lung Cancer
20%
Atrial Fibrillation
19%
Psychotropic Agent
19%
Anticoagulant Agent
19%
Antithrombotic Therapy
19%
Bleeding
17%
Non Small Cell Lung Cancer
15%
Antivitamin K
12%
Disease
11%
Multiple Chronic Conditions
9%
Peripheral Occlusive Artery Disease
9%
Diabetes Mellitus
9%
Antiplatelet
9%
Aortic Aneurysm
9%
Anticoagulation Therapy
9%
Abdominal Aortic Aneurysm
9%
Insulin Dependent Diabetes Mellitus
5%
Thromboembolism
5%
Cancer Staging
5%
Keyphrases
National Cohort Study
31%
Atrial Fibrillation
19%
Cancer Patients
12%
Venous Thromboembolism
11%
Pulmonary Embolism
11%
In Cancer
11%
Aneurysm Disease
9%
Increased Incidence
9%
Performance-based Outcome Measures
9%
PEmb-QoL
9%
Oral Anticoagulation
9%
Oral Anticoagulant Therapy
9%
Cancer-associated Venous Thromboembolism
9%
Patients with Schizophrenia
9%
Nationwide Cross-sectional Survey
9%
Patient Education
9%
1-year Follow-up
9%
Antiplatelet Therapy
9%
Lower Extremity Arterial Disease
9%
Danish Population
9%
Peripheral Arterial Disease
9%
Population-based Cohort Study
9%
PE Model
9%
Models of Care
9%
Bleeding
9%
Cardiovascular Outcomes
9%
Antithrombotic Therapy
9%
Schizophrenia
8%
Confidence Interval
7%
New User
7%
Proportion of Days Covered
6%
Terminal Illness
5%
First Year
5%